Cryo-Cell International (CCEL)
Market Price (12/25/2025): $3.5 | Market Cap: $28.2 MilSector: Health Care | Industry: Health Care Facilities
Cryo-Cell International (CCEL)
Market Price (12/25/2025): $3.5Market Cap: $28.2 MilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 17%, Dividend Yield is 19%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 13%, FCF Yield is 22% | Weak multi-year price returns2Y Excs Rtn is -82%, 3Y Excs Rtn is -95% | Weak revenue growthRev Chg QQuarterly Revenue Change % is -3.0% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 19% | Key risksCCEL key risks include the uncertain success of its strategic diversification, Show more. | |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -33% | ||
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Cellular & Regenerative Medicine, Personalized Diagnostics, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 17%, Dividend Yield is 19%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 13%, FCF Yield is 22% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 19% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -33% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Cellular & Regenerative Medicine, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -82%, 3Y Excs Rtn is -95% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -3.0% |
| Key risksCCEL key risks include the uncertain success of its strategic diversification, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Cryo-Cell International (CCEL) experienced a decline in its stock price, with several factors potentially contributing to the -26.6% movement between August 31, 2025, and December 25, 2025. Here are five key points: 1. 1. Decreased Revenue in Q3 2025: Cryo-Cell reported consolidated revenues of $7.83 million for the third quarter of fiscal 2025 (ended August 31, 2025), a 3% decrease compared to $8.07 million in the third quarter of fiscal 2024. This decline in revenue could negatively impact investor confidence. 2. 2. Lower Net Income in Q3 2025: The company's net income for the three months ended August 31, 2025, was $749,000, or $0.09 per basic and diluted share, down from $1.05 million, or $0.13 per basic and diluted share, for the same period in 2024. This represents a significant year-over-year decrease in profitability. 3. Show moreStock Movement Drivers
Fundamental Drivers
The -29.9% change in CCEL stock from 9/24/2025 to 12/24/2025 was primarily driven by a -29.5% change in the company's P/S Multiple.| 9242025 | 12242025 | Change | |
|---|---|---|---|
| Stock Price ($) | 4.92 | 3.45 | -29.88% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 31.99 | 31.75 | -0.75% |
| P/S Multiple | 1.24 | 0.88 | -29.54% |
| Shares Outstanding (Mil) | 8.08 | 8.06 | 0.28% |
| Cumulative Contribution | -29.88% |
Market Drivers
9/24/2025 to 12/24/2025| Return | Correlation | |
|---|---|---|
| CCEL | -29.9% | |
| Market (SPY) | 4.4% | 15.4% |
| Sector (XLV) | 14.2% | 3.7% |
Fundamental Drivers
The -32.0% change in CCEL stock from 6/25/2025 to 12/24/2025 was primarily driven by a -31.4% change in the company's P/S Multiple.| 6252025 | 12242025 | Change | |
|---|---|---|---|
| Stock Price ($) | 5.07 | 3.45 | -31.95% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 32.10 | 31.75 | -1.11% |
| P/S Multiple | 1.28 | 0.88 | -31.40% |
| Shares Outstanding (Mil) | 8.08 | 8.06 | 0.30% |
| Cumulative Contribution | -31.95% |
Market Drivers
6/25/2025 to 12/24/2025| Return | Correlation | |
|---|---|---|
| CCEL | -32.0% | |
| Market (SPY) | 14.0% | 9.8% |
| Sector (XLV) | 16.9% | 15.4% |
Fundamental Drivers
The -52.7% change in CCEL stock from 12/24/2024 to 12/24/2025 was primarily driven by a -52.6% change in the company's P/S Multiple.| 12242024 | 12242025 | Change | |
|---|---|---|---|
| Stock Price ($) | 7.29 | 3.45 | -52.67% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 31.84 | 31.75 | -0.29% |
| P/S Multiple | 1.85 | 0.88 | -52.56% |
| Shares Outstanding (Mil) | 8.06 | 8.06 | 0.05% |
| Cumulative Contribution | -52.67% |
Market Drivers
12/24/2024 to 12/24/2025| Return | Correlation | |
|---|---|---|
| CCEL | -52.7% | |
| Market (SPY) | 15.8% | 5.7% |
| Sector (XLV) | 13.3% | 9.5% |
Fundamental Drivers
The -12.2% change in CCEL stock from 12/25/2022 to 12/24/2025 was primarily driven by a -20.6% change in the company's P/S Multiple.| 12252022 | 12242025 | Change | |
|---|---|---|---|
| Stock Price ($) | 3.93 | 3.45 | -12.18% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 29.89 | 31.75 | 6.22% |
| P/S Multiple | 1.10 | 0.88 | -20.60% |
| Shares Outstanding (Mil) | 8.39 | 8.06 | 3.96% |
| Cumulative Contribution | -12.32% |
Market Drivers
12/25/2023 to 12/24/2025| Return | Correlation | |
|---|---|---|
| CCEL | -35.8% | |
| Market (SPY) | 48.9% | 4.8% |
| Sector (XLV) | 18.8% | 6.1% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CCEL Return | -12% | 84% | -64% | 36% | 33% | -48% | -45% |
| Peers Return | 93% | 6% | -42% | -9% | -0% | -11% | -5% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 115% |
Monthly Win Rates [3] | |||||||
| CCEL Win Rate | 17% | 25% | 8% | 42% | 42% | 33% | |
| Peers Win Rate | 54% | 52% | 42% | 44% | 50% | 48% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| CCEL Max Drawdown | -23% | 0% | -64% | -30% | -15% | -49% | |
| Peers Max Drawdown | -33% | -24% | -56% | -38% | -23% | -35% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: RVTY, CYRX, VCEL, PLUR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)
How Low Can It Go
| Event | CCEL | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -79.0% | -25.4% |
| % Gain to Breakeven | 376.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -26.3% | -33.9% |
| % Gain to Breakeven | 35.6% | 51.3% |
| Time to Breakeven | 531 days | 148 days |
| 2018 Correction | ||
| % Loss | -19.9% | -19.8% |
| % Gain to Breakeven | 24.8% | 24.7% |
| Time to Breakeven | 609 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -83.0% | -56.8% |
| % Gain to Breakeven | 487.5% | 131.3% |
| Time to Breakeven | 750 days | 1,480 days |
Compare to ACHC, SRTA, HCA, THC, UHS
In The Past
Cryo-Cell International's stock fell -79.0% during the 2022 Inflation Shock from a high on 9/2/2021. A -79.0% loss requires a 376.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-2 analogies to describe Cryo-Cell International (CCEL):
- It's like JPMorgan Chase, but for securely banking your baby's cord blood stem cells for potential future medical use instead of money.
- Think of it as a highly specialized Iron Mountain for biological material like cord blood, ensuring it's safely stored for potential future medical treatments.
AI Analysis | Feedback
- Cord Blood Banking: A private storage service for hematopoietic stem cells derived from umbilical cord blood for potential future medical use.
- Cord Tissue Banking: A private storage service for mesenchymal stem cells derived from umbilical cord tissue for potential future medical use.
- Menstrual Stem Cell Banking: A private storage service for mesenchymal-like stem cells derived from menstrual tissue for potential future medical use.
AI Analysis | Feedback
Cryo-Cell International (symbol: CCEL) primarily sells its services to individuals rather than other companies.
The company serves two primary categories of individual customers:
- Expectant Parents: This is Cryo-Cell's largest customer segment. These are individuals or couples who choose to privately bank their newborn's umbilical cord blood and/or cord tissue stem cells for potential future medical use by their family members. They pay for the collection, processing, and long-term cryogenic storage of these biological materials.
- Women seeking Personal Stem Cell Banking: Cryo-Cell also offers a service called C'elle, which allows individual women to collect and store their own menstrual stem cells. These customers are interested in banking their personal stem cells for potential future therapeutic applications.
AI Analysis | Feedback
nullAI Analysis | Feedback
David I. Portnoy, Chairman of the Board and Co-Chief Executive Officer
Mr. Portnoy has served as Chairman of the Board and Co-Chief Executive Officer of Cryo-Cell International since August 2011. He has also been the Chairman of the Board of Directors of Partner Community, Inc., a company focused on B2B integrations for telecommunication service providers, since 2002. His venture capital company led early-stage investment rounds in Waves Audio Ltd. Mr. Portnoy is an advocate of blockchain technology and cryptocurrencies, having acquired bitcoin in early 2012. He graduated Magna Cum Laude from The Wharton School of Finance at the University of Pennsylvania in 1984. In August 2011, he led a successful proxy fight that resulted in the replacement of Cryo-Cell International's board of directors.
Mark L. Portnoy, Director and Co-Chief Executive Officer
Mr. Portnoy has served as a Director and Co-Chief Executive Officer of Cryo-Cell International since August 2011. During his tenure, he has been instrumental in establishing a national sales force in 2012, adopting the Prepacyte-CB cord blood processing system in 2014, acquiring its exclusive worldwide rights in 2016, and purchasing Cord:Use Cord Blood Bank in 2018. Since 2002 and 2007, respectively, he has served on the boards of directors of Partner-Community, Inc. and uTIPu Inc., a private Internet-based business. Mr. Portnoy has managed his personal investments since April 1997. Previously, he was the Chief Fixed Income Trader at Strome, Susskind Investments from January 1995 to April 1997, and a Fixed Income Arbitrage Trader at Donaldson, Lufkin & Jenrette Securities Corp. from March 1986 to November 1991. He graduated Phi Beta Kappa from the University of North Carolina at Chapel Hill with a degree in Economics in December 1985.
Jill M. Taymans, Principal Accounting Officer, Vice President, Finance and Chief Financial Officer
Ms. Taymans has held the position of Chief Financial Officer at Cryo-Cell International since 1998. Prior to joining the company, she worked for three years as a Controller for a telecommunications company. With over 30 years of experience, Ms. Taymans has worked as an accountant in both the public and private sectors. She earned a BS in Accounting from the University of Maryland in 1991.
Oleg Mikulinsky, Chief Information Officer
Mr. Mikulinsky has served as Cryo-Cell's Chief Information Officer since March 2012. He is recognized as a software technologist and serial entrepreneur, having been a founding member of several software enterprises. His previous roles include Chief Technology Officer of Partner-Community, Inc. and Chief Technology Officer at uTIPu Inc. from 2007 to 2009. Mr. Mikulinsky also served as the Director of Enterprise Architecture at WebLayers, Inc., where he developed enterprise architecture best practices for major companies like AT&T and the Defense Information Systems Agency (DISA).
Todd Schuesler, Director of Laboratory Operations
Mr. Schuesler is responsible for Cryo-Cell's state-of-the-art laboratory, process improvements, and research. He also oversees PrepaCyte-CB, a 510K product that Cryo-Cell manufactures for internal use and other cord blood laboratories. Previously, Mr. Schuesler held positions in molecular, gene, and cellular therapies. While at Cincinnati Children's Hospital, he contributed to establishing the Translational Trials Development and Support Lab and was part of the team that introduced the hospital's first gene therapy clinical trial.
AI Analysis | Feedback
Cryo-Cell International (CCEL) faces several key risks to its business, primarily stemming from its strategic expansion and the dynamic nature of its industry.The most significant risk is the uncertainty and success of its new strategic initiatives, research and development (R&D), and clinical trials. Cryo-Cell is actively diversifying its core cord blood banking services by expanding into biopharmaceutical manufacturing, operating clinics, and developing advanced cellular therapies through collaborative research and clinical trials. The company is pursuing Phase 2 and Phase 3 clinical trials for conditions such as cerebral palsy, hypoxic ischemic encephalopathy, and autism spectrum disorder. The profitability and ultimate success of these new ventures, including securing necessary regulatory approvals (like Biologics License Applications, or BLAs), minimizing R&D costs, and successfully enforcing related intellectual property (IP) rights, are uncertain. Failure in any of these areas could materially and adversely affect the company's financial condition and future growth.
Secondly, Cryo-Cell International operates within an increasingly competitive landscape. The company competes against approximately 25 other national private cord blood banks, some of which may possess greater financial resources. This competitive environment can impact market share, pricing power, and the overall profitability of its core cord blood and cord tissue preservation services.
Finally, the company faces risks associated with the evolving regulatory environment and compliance requirements. Cryo-Cell is subject to strict and changing legislation and regulations governing private cord blood banking, including ongoing inspections and compliance with FDA regulations such as 21 CFR 1271 for cord blood. Additionally, its PrepaCyte CB Processing System must be registered as a Medical Device under the Federal Food, Drug, and Cosmetic Act, subjecting it to further FDA oversight. Changes in these regulations, or a failure to maintain compliance, could significantly impact the company's operations, product development, and ability to market its services.
AI Analysis | Feedback
nullAI Analysis | Feedback
Cryo-Cell International (CCEL) Addressable Markets
Cryo-Cell International's primary services revolve around the cellular processing and cryogenic storage of umbilical cord blood and tissue stem cells for both family and public use. The company also offers adipose tissue banking and has a patented method for processing endometrial stem cells from menstrual blood.
Cord Blood Banking Services
- Global Market: The global cord blood banking services market was valued at approximately USD 3.09 billion in 2024 and is projected to reach about USD 5.81 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 6.61% from 2025 to 2034. Other estimates place the global market at USD 37.13 billion in 2024, anticipated to reach USD 100.83 billion by 2032, at a CAGR of 13.29%. Another report estimates the global umbilical cord blood banking market to reach US$ 7.9 billion by 2031 from US$ 3.4 billion in 2023, with an 11.00% CAGR.
- U.S. Market: The U.S. cord blood banking services market was estimated at USD 1.05 billion in 2024 and is projected to reach approximately USD 1.65 billion by 2034, with a CAGR of 4.6% from 2025 to 2034. Another source indicates the U.S. market was valued at USD 6.83 billion in 2022 and is expected to grow to USD 16.59 billion by 2030, with a CAGR of 11.56% from 2023 to 2030. In 2023, the U.S. cord blood banking services market captured a significant market of 9.57 billion.
Cord Tissue Banking Services
While specific separate market size figures for cord tissue banking alone are often integrated within broader cord blood banking reports, the cord tissue segment consistently dominates the cord blood banking services market by component. It is projected to expand at a significant CAGR from 2024 to 2030. This dominance is attributed to cord tissue's rich supply of mesenchymal stem cells (MSCs) and their potential in regenerative medicine.
Mesenchymal Stem Cells (MSCs) Market
Cryo-Cell International's services indirectly contribute to the mesenchymal stem cells market through cord tissue banking.
- Global Market: The global mesenchymal stem cells market size was valued at USD 226.16 million in 2025 and is expected to reach USD 337.36 million by 2034, growing at a CAGR of 4.5% from 2025 to 2034. Other estimates suggest the global market was USD 3,124.1 million in 2023 and is projected to reach USD 7,266.4 million by 2030, growing at a CAGR of 12.9% from 2024 to 2030. The mesenchymal stem cell therapy market specifically was estimated at USD 80.95 million in 2024 and is projected to reach approximately USD 679.07 million by 2034, with a CAGR of 23.70% from 2025 to 2034.
- U.S. Market: The U.S. market for mesenchymal stem cells is projected at USD 52.36 million in 2025 and is expected to advance to USD 78.35 million by 2034, with a CAGR of 4.7%.
Stem Cell Banking Market (Broader Context)
As a provider of cord blood and tissue banking, Cryo-Cell International operates within the larger stem cell banking market.
- Global Market: The global stem cell banking market size is estimated at USD 7.85 billion in 2024, projected to grow to USD 9.12 billion in 2025, and reach approximately USD 35.12 billion by 2034, at a CAGR of 16.14% from 2025 to 2034. Another report indicates the global stem cell banking market size was USD 6.68 billion in 2024 and is expected to reach around USD 24.68 billion by 2033, expanding at a CAGR of 15.63% from 2024 to 2033.
- North American Market: North America held a dominant revenue share of 35-40% in the global stem cell banking market in 2024. The U.S. stem cells market size was exhibited at USD 5.13 billion in 2024 and is projected to reach approximately USD 15.79 billion by 2034, growing at a CAGR of 11.9% during the forecast period 2024 to 2034.
AI Analysis | Feedback
Cryo-Cell International (CCEL) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and existing strengths:
- Expansion into Cellular Therapies and Clinic Operations: Cryo-Cell anticipates opening infusion clinics to treat patients with conditions such as autism, cerebral palsy, and traumatic brain injuries, leveraging an exclusive collaborative license agreement with Duke University. This agreement grants Cryo-Cell rights to intellectual property, proprietary processes, and regulatory/clinical data related to cord blood and cord tissue developed at Duke University, positioning the company to develop, manufacture, and administer cellular therapies.
- Growth of ExtraVault Biostorage Services: The company launched ExtraVault in March 2022 to provide biostorage and distribution services to biopharmaceutical companies and healthcare institutions. This diversification into offering specialized biostorage solutions is supported by Cryo-Cell's new 56,000-square-foot facility in Durham, North Carolina, opened in 2024, which is designed for advanced biotech operations and cryogenic storage.
- Continued Growth in Core Cord Blood and Cord Tissue Banking: As the world's first private cord blood bank, Cryo-Cell International continues to focus on its core service of providing state-of-the-art cord blood and cord tissue cryopreservation. The company has over 500,000 parents from 87 countries who have entrusted their baby's cord blood and tissue stem cells to Cryo-Cell. Fiscal year 2024 saw consolidated revenues increase to $32.0 million from $31.3 million in fiscal year 2023, with processing and storage fees being the primary component.
- Leveraging Advanced Processing Technology and Intellectual Property: Cryo-Cell holds exclusive rights to PrepaCyte-CB, which it describes as the industry's most advanced cord blood processing technology. The company also states that it holds more cord blood patents through its research affiliate than any other cord blood bank, which provides a competitive advantage that can attract customers seeking superior technology and potentially lead to market share gains.
AI Analysis | Feedback
```htmlShare Issuance
- The 2022 Stock Incentive Plan authorized the issuance of 1,500,000 shares of common stock for stock options, restricted stock, and other awards.
- Shares of common stock outstanding increased from 7,570,913 as of February 15, 2021, to 8,082,159 as of February 28, 2025.
Inbound Investments
- In February 2021, Cryo-Cell International entered into an exclusive license agreement with Duke University, granting the company rights to intellectual property, proprietary processes, and regulatory/clinical data related to cord blood and cord tissue.
Outbound Investments
- In March 2022, Cryo-Cell launched ExtraVault, a new business unit to offer biostorage and distribution services to biopharmaceutical companies and healthcare institutions.
- The company has plans to expand into cord blood and cord tissue infusion clinic services, though these initiatives are currently on pause due to ongoing legal proceedings with Duke University.
Capital Expenditures
- Net Property, Plant, and Equipment saw a significant increase from $1.94 million in November 2020 to $22.7 million in November 2024, indicating substantial capital investments over this period.
- For the three months ended August 31, 2025, net cash used in investing activities, primarily for equipment purchases, totaled $0.69 million.
- Future capital expenditures are anticipated for establishing biopharmaceutical manufacturing capabilities and operating clinics, although the opening of new clinics is currently paused.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| Cryo-Cell International Earnings Notes | ||
| Can Cryo-Cell International Stock Recover If Markets Fall? | Return |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CCEL. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 20.9% | 20.9% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 13.5% | 13.5% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 1.6% | 1.6% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.8% | 11.8% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Cryo-Cell International
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 9.77 |
| Mkt Cap | 0.5 |
| Rev LTM | 244 |
| Op Inc LTM | 4 |
| FCF LTM | 6 |
| FCF 3Y Avg | 3 |
| CFO LTM | 6 |
| CFO 3Y Avg | 7 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 14.1% |
| Rev Chg 3Y Avg | 5.2% |
| Rev Chg Q | 2.2% |
| QoQ Delta Rev Chg LTM | 0.5% |
| Op Mgn LTM | 2.7% |
| Op Mgn 3Y Avg | -1.6% |
| QoQ Delta Op Mgn LTM | 1.7% |
| CFO/Rev LTM | 20.0% |
| CFO/Rev 3Y Avg | 15.2% |
| FCF/Rev LTM | 7.9% |
| FCF/Rev 3Y Avg | 2.9% |
Price Behavior
| Market Price | $3.45 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -57.3% | |
| 50 Days | 200 Days | |
| DMA Price | $4.14 | $4.85 |
| DMA Trend | down | down |
| Distance from DMA | -16.7% | -28.8% |
| 3M | 1YR | |
| Volatility | 50.8% | 58.4% |
| Downside Capture | 99.01 | 79.37 |
| Upside Capture | -86.75 | -6.82 |
| Correlation (SPY) | 15.7% | 5.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.80 | 0.52 | 0.55 | 0.48 | 0.18 | 0.18 |
| Up Beta | 2.92 | 2.66 | 2.22 | 1.59 | 0.06 | -0.11 |
| Down Beta | 0.56 | -0.19 | -0.30 | -0.52 | -0.05 | 0.49 |
| Up Capture | -57% | -30% | -4% | 6% | 2% | 5% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 10 | 20 | 28 | 52 | 113 | 346 |
| Down Capture | 79% | 65% | 88% | 100% | 89% | 47% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 9 | 19 | 31 | 68 | 129 | 382 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of CCEL With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| CCEL | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -53.6% | 16.4% | 19.2% | 71.9% | 8.9% | 6.0% | -10.4% |
| Annualized Volatility | 58.0% | 17.3% | 19.5% | 19.3% | 15.3% | 17.1% | 35.0% |
| Sharpe Ratio | -1.10 | 0.72 | 0.78 | 2.69 | 0.36 | 0.18 | -0.12 |
| Correlation With Other Assets | 9.3% | 5.6% | 4.3% | 0.2% | 13.9% | 10.0% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of CCEL With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| CCEL | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -11.2% | 8.6% | 14.9% | 18.7% | 11.7% | 4.8% | 32.6% |
| Annualized Volatility | 78.2% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.7% |
| Sharpe Ratio | 0.15 | 0.41 | 0.70 | 0.97 | 0.51 | 0.17 | 0.59 |
| Correlation With Other Assets | 1.5% | 3.0% | 1.3% | 3.3% | 5.3% | 3.9% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of CCEL With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| CCEL | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -8.4% | 9.8% | 14.7% | 14.9% | 6.9% | 5.2% | 69.2% |
| Annualized Volatility | 75.1% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.11 | 0.48 | 0.70 | 0.83 | 0.31 | 0.22 | 0.90 |
| Correlation With Other Assets | 2.2% | 4.3% | 2.9% | 4.3% | 6.6% | 3.3% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/17/2024 | 2.5% | 0.2% | 40.2% |
| 2/24/2022 | -0.1% | -1.5% | -6.9% |
| 10/15/2021 | -3.5% | -4.2% | -5.8% |
| 7/19/2021 | 0.0% | 0.0% | 0.0% |
| 2/25/2021 | 0.0% | 0.0% | 0.0% |
| 10/19/2020 | 0.0% | 0.0% | 0.0% |
| 7/13/2020 | 0.0% | 0.0% | 0.0% |
| 3/2/2020 | 0.0% | -0.3% | -11.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 8 | 6 |
| # Negative | 2 | 4 | 6 |
| Median Positive | 0.0% | 0.0% | 0.0% |
| Median Negative | -1.8% | -2.8% | -7.1% |
| Max Positive | 2.5% | 2.1% | 40.2% |
| Max Negative | -3.5% | -5.5% | -11.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 8312025 | 10152025 | 10-Q 8/31/2025 |
| 5312025 | 7152025 | 10-Q 5/31/2025 |
| 2282025 | 4142025 | 10-Q 2/28/2025 |
| 11302024 | 2282025 | 10-K 11/30/2024 |
| 8312024 | 10152024 | 10-Q 8/31/2024 |
| 5312024 | 7152024 | 10-Q 5/31/2024 |
| 2292024 | 4152024 | 10-Q 2/29/2024 |
| 11302023 | 2282024 | 10-K 11/30/2023 |
| 8312023 | 10122023 | 10-Q 8/31/2023 |
| 5312023 | 7142023 | 10-Q 5/31/2023 |
| 2282023 | 4212023 | 10-Q 2/28/2023 |
| 11302022 | 2282023 | 10-K 11/30/2022 |
| 8312022 | 10182022 | 10-Q 8/31/2022 |
| 5312022 | 7112022 | 10-Q 5/31/2022 |
| 2282022 | 4132022 | 10-Q 2/28/2022 |
| 11302021 | 2222022 | 10-K 11/30/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.